अध्ययन का उद्देश्य: The goal of this Phase I clinical research study is to determine the tolerable dose of the combination of Afinitor (everolimus) either with Kineret (anakinra) or Xgeva (denosumab) for patients with advanced cancer. Everolimus is designed to stop cells from dividing. Anakinra is designated to block a protein that is involved in tumor development, new blood vessels growing, and spread of cancer. Denosumab is designed to block the activity of a protein, which may prevent bone complications in cancer that has spread to the bone.
प्रायोजक: M.D. Anderson Cancer Center
परीक्षण संपर्क जानकारी: Veronica Holley; VRHolley@mdanderson.org Filip Janku; 713-563-1930; FJanku@mdanderson.org
अनुरोधित रोगी सहभागिता: ECD patients at least 18 years of age. Patients may be BRAF positive or negative.
ट्रायल में ECD रोगियों को स्वीकार करने वाले ज्ञात केंद्र: एमडी एंडरसन, ह्यूस्टन, टेक्सास
ClinicalTrials.gov पहचानकर्ता: NCT01624766